Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled …

K Zaman, AS Bandyopadhyay, M Hoque, C Gast… - The Lancet, 2023 - thelancet.com
Background Type 2 circulating vaccine-derived polioviruses (cVDPV2) from Sabin oral
poliovirus vaccines (OPVs) are the leading cause of poliomyelitis. A novel type 2 OPV …

Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised …

AL Wilkinson, K Zaman, M Hoque… - The Lancet Infectious …, 2023 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the
Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine …

Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to< 5 years and lot-to-lot consistency of the immune response to …

M Ochoge, AC Futa, A Umesi, L Affleck, L Kotei… - The Lancet, 2024 - thelancet.com
Background Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve
the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of …

Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The …

AO Bashorun, L Kotei, O Jawla, AF Jallow… - The Lancet Infectious …, 2024 - thelancet.com
Background Novel oral polio vaccine type 2 (nOPV2) has been used to interrupt circulating
vaccine-derived poliovirus type 2 outbreaks following its WHO emergency use listing. This …

Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials

TJ John, H Jain, K Ravishankar, A Amaresh, H Verma… - Vaccine, 2011 - Elsevier
BACKGROUND: To provide the polio eradication initiative with more immunogenic oral
poliovirus vaccines (OPVs), we evaluated newly developed monovalent type 1 OPV …

Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study

M Taniuchi, M Famulare, K Zaman… - The Lancet Infectious …, 2017 - thelancet.com
Background Trivalent oral polio vaccine (tOPV) was replaced worldwide from April, 2016, by
bivalent types 1 and 3 oral polio vaccine (bOPV) and one dose of inactivated polio vaccine …

Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label …

CF Estívariz, A Anand, HE Gary, M Rahman… - The Lancet Infectious …, 2015 - thelancet.com
Background The provision of several doses of monovalent type 1 oral poliovirus vaccine
(mOPV1) and bivalent OPV1 and 3 (bOPV) vaccines through campaigns is essential to stop …

Effect of diarrhea on the humoral response to oral polio vaccination

JA Myaux, L Unicomb, RE Besser… - The Pediatric …, 1996 - journals.lww.com
Objective The purpose of this study was to measure the effect of concurrent diarrheal illness
on seroconversion to trivalent oral polio vaccine (OPV). Methods Six-to 16-week-old infants …

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants …

X Sáez-Llorens, AS Bandyopadhyay, C Gast… - The Lancet, 2021 - thelancet.com
Background Continued emergence and spread of circulating vaccine-derived type 2
polioviruses and vaccine-associated paralytic poliomyelitis from Sabin oral poliovirus …

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised …

J John, S Giri, AS Karthikeyan, M Iturriza-Gomara… - The Lancet, 2014 - thelancet.com
Background Intestinal immunity induced by oral poliovirus vaccine (OPV) is imperfect and
wanes with time, permitting transmission of infection by immunised children. Inactivated …